相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular Complications of Cancer Therapy Best Practices in Diagnosis, Prevention, and Management: Part 2
Hui-Ming Chang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma
H. Izzedine et al.
ANNALS OF ONCOLOGY (2015)
Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
Rana R. McKay et al.
CLINICAL CANCER RESEARCH (2015)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people
Eleni Rapsomaniki et al.
LANCET (2014)
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
E. Pasquier et al.
BRITISH JOURNAL OF CANCER (2013)
Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1
Stephanie Lankhorst et al.
JOURNAL OF HYPERTENSION (2013)
The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells
R. Preston Mason et al.
BMC PHARMACOLOGY & TOXICOLOGY (2013)
Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1
Nilka de Jesus-Gonzalez et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
Mariette H. W. Kappers et al.
HYPERTENSION (2012)
Management of Antiangiogenic Therapy-Induced Hypertension
Nilka de Jesus-Gonzalez et al.
HYPERTENSION (2012)
Treatment of bevacizumab-induced hypertension by amlodipine
Olivier Mir et al.
INVESTIGATIONAL NEW DRUGS (2012)
Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System
Babak Nazer et al.
CIRCULATION (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor
Emily S. Robinson et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
Mao Mao An et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
Mariette H. W. Kappers et al.
HYPERTENSION (2010)
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Michael L. Maitland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
Michael L. Maitland et al.
CLINICAL CANCER RESEARCH (2009)
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
Carie S. Facemire et al.
HYPERTENSION (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors
Goodarz Danaei et al.
PLOS MEDICINE (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant anti hypertensive therapy
Jon O. Curwen et al.
CLINICAL CANCER RESEARCH (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
Tejas V. Patel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Home blood-pressure monitoring in patients receiving sunitinib
Michel Azizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides et al.
NATURE REVIEWS CANCER (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
Felix Boehm et al.
CARDIOVASCULAR RESEARCH (2007)
Platelets take up the monoclonal antibody bevacizumab
Henk M. W. Verheu et al.
CLINICAL CANCER RESEARCH (2007)
The glomerular injury of preeclampsia
Isaac E. Stillman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Manish Jain et al.
CURRENT HYPERTENSION REPORTS (2007)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors
L. Y. Dirix et al.
ANNALS OF ONCOLOGY (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension
Murat Dincer et al.
ANNALS OF PHARMACOTHERAPY (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway
Shin-ichiro Miura et al.
HYPERTENSION RESEARCH (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Prognostic importance of Comorbidity in a hospital-based cancer registry
JF Piccirillo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Expression of hypoxia-inducible factor-lα is associated with tumor vascularization in human colorectal carcinoma
T Kuwai et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
